What is claimed is:

1. Use of an inhalable insulin formulation comprising human insulin and 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine in the manufacture of a medicament for the treatment of hyperglycemia, wherein an initial predetermined dose of 15 to 90 Units of the inhalable insulin formulation is to be administered by oral inhalation at mealtime, and wherein a second dose of 25% to 100% of the initial dose is to be administered if postprandial blood glucose level is determined to be greater than 140 mg/dl 1 to 2 hours after beginning a meal.

2. The use of claim 1, wherein the inhalable insulin formulation is an ultrarapid acting insulin formulation.

3. The use of claim 1 or claim 2, wherein the inhalable insulin formulation is provided in a dose cartridge comprising 4, 8, or 12 subcutaneous equivalent (subQ eq) units.

4. The use of claim 3, wherein the dose cartridge comprises 4 subQ eq units.

5. The use of claim 3, wherein the dose cartridge comprises 8 subQ eq units.

6. The use of claim 3, wherein the dose cartridge comprises 12 subQ eq units.

7. The use of claim 2, wherein the medicament is to be administered to a patient in combination with a dose of a long acting insulin analog which is to be administered within 6 hours of waking for a day.

8. The use of claim 1, wherein the initial predetermined dose is 15 Units.

9. The use of claim 1, wherein the medicament is formulated as a dry powder.

10. The use of claim 1, wherein the inhalable insulin formulation is not to be administered by injection.